Cargando…

Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia

Detalles Bibliográficos
Autores principales:	Li, Xia, Yin, Xiufeng, Wang, Huafeng, Huang, Jiansong, Yu, Mengxia, Ma, Zhixin, Li, Chenying, Zhou, Yile, Yan, Xiao, Huang, ShuJuan, Jin, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859928/ https://www.ncbi.nlm.nih.gov/pubmed/31762943 http://dx.doi.org/10.18632/oncotarget.27310

Ejemplares similares

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2017)

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3 ‐ITD
por: Qian, Yu, et al.
Publicado: (2023)

Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells
por: Chen, Jian, et al.
Publicado: (2017)

Homoharringtonine Synergized with Gilteritinib Results in the Downregulation of Myeloid Cell Leukemia-1 by Upregulating UBE2L6 in FLT3-ITD-Mutant Acute Myeloid (Leukemia) Cell Lines
por: Cai, Jiayi, et al.
Publicado: (2021)

Homoharringtonine Combined with the Heat Shock Protein 90 Inhibitor IPI504 in the Treatment of FLT3-ITD Acute Myeloid Leukemia
por: Wu, Zhaoxing, et al.
Publicado: (2019)

Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells
por: Liu, Xiao-Jian, et al.
Publicado: (2020)

Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
por: Wei, Wenwen, et al.
Publicado: (2022)

Feature genes predicting the FLT3/ITD mutation in acute myeloid leukemia
por: LI, CHENGLONG, et al.
Publicado: (2016)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
por: Burchert, Andreas
Publicado: (2021)

MicroRNA networks in FLT3-ITD acute myeloid leukemia
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD(+) acute myeloid leukemia
por: Li, Dan, et al.
Publicado: (2020)

Prognostic impact of MYH9 expression on patients with acute myeloid leukemia
por: Yu, Mengxia, et al.
Publicado: (2016)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
por: Haage, Tobias R., et al.
Publicado: (2023)

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
por: Pillinger, Genevra, et al.
Publicado: (2015)

Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia
por: Sies, Katharina, et al.
Publicado: (2019)

A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice
por: Mupo, A, et al.
Publicado: (2013)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia
por: Matsukawa, Toshihiro, et al.
Publicado: (2023)

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia
por: Naseem, Shano, et al.
Publicado: (2021)

Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC
por: Li, Chenying, et al.
Publicado: (2020)

NADPH oxidase mediated oxidative stress signaling in FLT3-ITD acute myeloid leukemia
por: Chen, Yongfeng, et al.
Publicado: (2023)

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
por: Wang, Peihong, et al.
Publicado: (2021)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era
por: Choi, Sujin, et al.
Publicado: (2020)

Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios
por: Qiu, Kun-yin, et al.
Publicado: (2022)

Cytoplasmic DROSHA and Non-canonical Mechanisms of MiR-155 Biogenesis in FLT3-ITD Acute Myeloid Leukemia
por: Nguyen, Le Xuan Truong, et al.
Publicado: (2021)

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2015)

An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia
por: Lopez, Sophie, et al.
Publicado: (2016)

Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia
por: Heydt, Q, et al.
Publicado: (2018)

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD(+) acute myeloid leukemia
por: Ueno, Yoko, et al.
Publicado: (2019)

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
por: He, Bai‐Liang, et al.
Publicado: (2020)

Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia
por: Lopez‐Reyes, Rosa G., et al.
Publicado: (2020)

Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo
por: Spohr, Corinna, et al.
Publicado: (2021)

CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia
por: Karnan, Sivasundaram, et al.
Publicado: (2021)

Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD(+) Acute Myeloid Leukemia
por: Bregante, Javier, et al.
Publicado: (2021)

PB1856: MUTATION STATUS AND ALLELE BURDEN OF FLT3-ITD IN ACUTE MYELOID LEUKEMIA
por: Radzhabova, Asiyat, et al.
Publicado: (2023)

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects
por: Li, Xia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6gcl6kr2e65kukgrb7dkiedk84